Compound Forms definition

Compound Forms means, with respect to a particular compound, any pharmaceutically acceptable salt forms, free acids or bases, hydrates, anhydrides, solvates, racemates, isomers, positional isomers, radioisomers, stereoisomers, polymorphs, prodrugs, or metabolites of such compound.
View Source
Compound Forms means, with respect to the Company Compound, any and all metabolic precursors or prodrugs, isomers, hydrates, anhydrides, solvates, salt forms, free acids or bases, esters, amides, complexes, conjugates, polymorphs, tautomers, amorphous forms or co-crystals or other physical forms or co-forms of such Company Compound, to the extent owned or controlled by the Company.
View Source

Examples of Compound Forms in a sentence

  • During the term of this Agreement, all data, information and other documentation of either party, to the extent that they relate to Compound, Bulk Tablets and Product (and Compound Forms and Related Compounds, if any), shall be deemed the confidential information of both parties within the meaning of Section 10 (Confidentiality), each party to be deemed the “Receiving Party” of all such data, information and other documentation, permitted to use it only as permitted above.

  • For all of the Acquired Companies nonclinical studies or clinical trials concerning a Product and/or the Company Compound, including any Compound Forms thereof, the study reports, protocols, and statistical analysis plans accurately and completely reflects the results from and plans for such studies and trials in all material respects.

  • After the Research Term, Licensee shall not, directly or indirectly, [***] any [***], and Compound Forms thereof, other than (i) in the [***] Licensed Compounds and Licensed Products; (ii) to perform its obligations under this Agreement; and (iii) to conduct [***].

  • In addition, Otsuka (and not BMS) shall own all data, information and other documentation (including, without limitation, all scientific, clinical and commercial data, information and documentation) concerning Compound, Bulk Tablets and Product (and Compound Forms and Related Compounds, if any) developed by BMS as the same pertain to the Reserved Territory, the United States and/or the European Union, while BMS shall own the same in the Rest of Territory during the term of the Agreement.

  • Each party shall provide all such assistance as is reasonably requested by the other in the preparation and conduct of any such meetings, conferences and discussions, including any inspections by Regulatory Authorities with respect to the Product and/or the Company Compound, including any Compound Forms thereof.

  • No Company Representative or scientific advisor of an Acquired Company has excluded, in any agreement with an Acquired Company, any inventions, methods, processes, compounds, developments or other Intellectual Property that relate to the business of any Acquired Company, including the Product, the Company Compound, including any Compound Forms thereof, and/or Company Intellectual Property.

  • From and after the Execution Date through the Closing Date, the Company shall provide Parent with advance notice of all meetings, conferences, and discussions scheduled with Regulatory Authorities concerning any regulatory matters relating to the Product and/or the Company Compound, including any Compound Forms thereof, not later than five days after the Company receives notice of the scheduling of such meeting, conference, or discussion.

  • In addition, Otsuka shall continue during the term of this Agreement to provide BMS with relevant development data, information and other documentation coming into its possession concerning Compound, Bulk Tablets and Product (and Compound Forms and Related Compounds, if relevant), subject to the limitation in the preceding paragraph regarding manufacturing-related data, information and other documentation.

  • For purposes of this Agreement, “Improvements” shall mean any and all inventions, discoveries, improvements, pharmaceutical formulations, new indications, chemical processes, data (preclinical, clinical or otherwise), information and know-how (whether or not maintained as trade secret), whether or not patented or patentable, relating to the Compound, Compound Forms, Related Compounds, Product or the manufacture or use of any of them.

  • Subject to the terms and conditions of this Agreement, Licensee hereby grants to ▇▇▇▇▇▇▇ and its Affiliates, after expiration of the Research Term, [***] (subject to Licensee’s rights under Section 2.1.4 (Declined Compound License)), royalty-free, fully paid-up license, with the right to grant sublicenses (through multiple tiers), under the [***] and any Compound Forms thereof and products containing any such [***].

Related to Compound Forms

  • IND means (a) an Investigational New Drug Application as defined in the FD&C Act and applicable regulations promulgated thereunder by the FDA, or (b) the equivalent application to the equivalent agency in any other regulatory jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • DMF means a drug master file, as provided for in 21 CFR § 314.420 or similar submission to or file maintained with the FDA or other Governmental Authority or Regulatory Authority that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid, a quantity of soluble lead compound exceeding, when calculated as lead monoxide, five per cent of the “dry weight” of the portion taken for analysis. In the case of paints and similar products and other mixtures containing oil or fat the “dry weight” means the dry weight of the material remaining after the substance has been thoroughly mixed and treated with suitable solvents to remove oil, fats, varnish or other media.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).